C. Zarate | Semantic Scholar

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

C. Zarate, Jaskaran Singh, H. Manji
Psychology, Medicine
Archives of general psychiatry
1 August 2006

Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.

View on PubMed

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

S. Maeng, C. Zarate, H. Manji
Biology, Psychology
Biological Psychiatry
15 February 2008

View on Elsevier

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

P. Zanos, R. Moaddel, T. Gould
Psychology, Biology
Nature
24 April 2016

It is shown that the metabolism of (R,S)-ketamine to (2S,6S;2R,6R)-hydroxynorketamine (HNK) is essential for its antidepressant effects, and that the HNK enantiomer exerts behavioural, electroencephalographic, electrophysiological and cellular antidepressant-related actions in mice.

View on Nature

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

G. Sanacora, C. Zarate, J. Krystal, H. Manji
Psychology, Biology
Nature Reviews Drug Discovery
1 May 2008

There is growing evidence that the glutamatergic system is central to the neurobiology and treatment of mood disorders and exciting new prospects for the development of improved therapeutics for these devastating disorders are discussed.

View on Nature

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

N. Diazgranados, Lobna A Ibrahim, C. Zarate
Psychology
Archives of general psychiatry
1 August 2010

In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate-receptor antagonist.

View on PubMed

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

C. Zarate, N. Brutsche, D. Luckenbaugh
Psychology, Medicine
Biological Psychiatry
1 June 2012

View on Elsevier

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

N. Diazgranados, Lobna A Ibrahim, C. Zarate
Psychology, Medicine
The Journal of clinical psychiatry
13 July 2010

Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion.

View on PubMed

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

H. Manji, J. Quiroz, D. Charney
Biology
Biological Psychiatry
15 April 2003

View on Elsevier

Ketamine for Depression: Where Do We Go from Here?

M. Rot, C. Zarate, D. Charney, S. Mathew
Psychology, Medicine
Biological Psychiatry
1 October 2012

View on Elsevier

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

P. Zanos, R. Moaddel, T. Gould
Biology, Psychology
Pharmacological Reviews
26 June 2018

Pharmacological target deconvolution of ketamine and its metabolites will provide insight critical to the development of new pharmacotherapies that possess the desirable clinical effects of ketamines, but limit undesirable side effects.

View on Publisher